JBM (Healthcare) Limited develops, manufactures, distributes, and markets healthcare and wellness products in Asia. More Details
Imperfect balance sheet with poor track record.
Share Price & News
How has JBM (Healthcare)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2161 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: Insufficient data to determine 2161's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how 2161 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2161 performed against the Hong Kong Market.
Long-Term Price Volatility Vs. Market
How volatile is JBM (Healthcare)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is JBM (Healthcare) undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 2161 (HK$1.65) is trading above our estimate of fair value (HK$0.25)
Significantly Below Fair Value: 2161 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 2161 is poor value based on its PE Ratio (29x) compared to the Hong Kong Pharmaceuticals industry average (14.3x).
PE vs Market: 2161 is poor value based on its PE Ratio (29x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2161's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2161 is overvalued based on its PB Ratio (1.8x) compared to the HK Pharmaceuticals industry average (1.3x).
How is JBM (Healthcare) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as JBM (Healthcare) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has JBM (Healthcare) performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2161 has high quality earnings.
Growing Profit Margin: 2161's current net profit margins (10.8%) are lower than last year (17%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2161's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: 2161's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2161 had negative earnings growth (-21.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.2%).
Return on Equity
High ROE: 2161's Return on Equity (6.2%) is considered low.
How is JBM (Healthcare)'s financial position?
Financial Position Analysis
Short Term Liabilities: 2161's short term assets (HK$270.1M) exceed its short term liabilities (HK$99.9M).
Long Term Liabilities: 2161's short term assets (HK$270.1M) do not cover its long term liabilities (HK$553.7M).
Debt to Equity History and Analysis
Debt Level: 2161's debt to equity ratio (69.1%) is considered high.
Reducing Debt: Insufficient data to determine if 2161's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 2161's debt is not well covered by operating cash flow (7.8%).
Interest Coverage: 2161 earns more interest than it pays, so coverage of interest payments is not a concern.
What is JBM (Healthcare) current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2161's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2161's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2161's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2161's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2161's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Patrick Wong (56 yo)
Mr. Yat Wai Wong is also known as Patrick is Chief Executive Director and Executive Director at JBM (Healthcare) Limited since January 7, 2020. He joined the Company and its subsidiaries since January 7, 2...
Experienced Board: 2161's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: 2161 only recently listed within the past 12 months.
JBM (Healthcare) Limited's company bio, employee growth, exchange listings and data sources
- Name: JBM (Healthcare) Limited
- Ticker: 2161
- Exchange: SEHK
- Founded: 2020
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$1.475b
- Shares outstanding: 893.69m
- Website: https://www.jbmhealthcare.com.hk
- JBM (Healthcare) Limited
- Unit 2303-07, Tower 1
- 23rd Floor, Millennium City 1
- Kwun Tong
- Hong Kong
JBM (Healthcare) Limited develops, manufactures, distributes, and markets healthcare and wellness products in Asia. It offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/12 14:46|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.